PRO 2000/5 Gel — Competitive Intelligence Brief

PRO 2000/5 Gel (PRO 2000/5 Gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: microbicide. Area: Infectious Diseases.

phase 3 microbicide gp120 Infectious Diseases Small molecule

Target snapshot

PRO 2000/5 Gel (PRO 2000/5 Gel) — National Institute of Allergy and Infectious Diseases (NIAID). PRO 2000/5 Gel is a microbicide that prevents HIV-1 transmission by inhibiting viral entry into host cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PRO 2000/5 Gel TARGET	PRO 2000/5 Gel	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	microbicide	gp120
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
All licensed antiretroviral medications	All licensed antiretroviral medications	University of Minnesota	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41)
HIV therapy	HIV therapy	ViiV Healthcare	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple targets depending on specific agent (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5 co-receptor, gp120/gp41 envelope proteins)
Antiretroviral medications	Antiretroviral medications	French National Agency for Research on AIDS and Viral Hepatitis	phase 3	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41
MN rgp120/HIV-1 and A244 rgp120/HIV-1	MN rgp120/HIV-1 and A244 rgp120/HIV-1	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	HIV vaccine	gp120 (HIV-1 envelope glycoprotein)
BMS-663068	BMS-663068	ViiV Healthcare	phase 3	HIV attachment inhibitor	HIV gp120 envelope protein / CD4 receptor interaction

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (microbicide class)

1. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class